-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – 4D-710 in Cystic Fibrosis
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - 4D-710 in Cystic Fibrosis report and make more profitable business decisions. This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. 4D-710 in Cystic Fibrosis Drug Details: 4D-710 is under development for...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – 4D-150 in Diabetic Macular Edema
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - 4D-150 in Diabetic Macular Edema report and make more profitable business decisions.This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. 4D-150 in Diabetic Macular Edema Drug Details: 4D-150 is under development...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – 4D-125 in Retinitis Pigmentosa (Retinitis)
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - 4D-125 in Retinitis Pigmentosa (Retinitis) report and make more profitable business decisions. This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. 4D-125 in Retinitis Pigmentosa (Retinitis) Drug Details: 4D-125 is under...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – 4D-150 in Wet (Neovascular / Exudative) Macular Degeneration
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - 4D-150 in Wet (Neovascular / Exudative) Macular Degeneration report and make more profitable business decisions.This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. 4D-150 in Wet (Neovascular / Exudative) Macular Degeneration...
-
Sector Analysis
NewUltrasound Systems Market Size by Segments, Share, Regulatory, Reimbursement, Installed Base and Forecast to 2033
Ultrasound Systems Market Report Overview The ultrasound systems market size was $6.48 billion in 2023 and will grow at a CAGR of more than 1% during 2023-2033. The ultrasound systems market is driven by increased demand for minimally invasive diagnostic & therapeutic techniques, rising elderly patient populations, and technological advancements. Furthermore, growth in the global economy and private healthcare insurance companies in countries such as Brazil, Saudi Arabia, and South Africa will further boost the adoption of ultrasound systems. Ultrasound...
-
Product Insights
NewNet Present Value Model: 4D Pharma Plc’s MRx-4DP0004
Empower your strategies with our Net Present Value Model: 4D Pharma Plc's MRx-4DP0004 report and make more profitable business decisions. Evaluating the value of drugs can be complex, involving a deep understanding of the drug, the current market and expected cash flows, expenses, and success rates at each stage of development. Fortunately, GlobalData simplifies this process with meticulously crafted, high-value, risk-adjusted NPV models that incorporate extensive drug intelligence.
-
Product Insights
NewNet Present Value Model: 4D Pharma Plc’s MRx-518
Empower your strategies with our Net Present Value Model: 4D Pharma Plc's MRx-518 report and make more profitable business decisions. Evaluating the value of drugs can be complex, involving a deep understanding of the drug, the current market and expected cash flows, expenses, and success rates at each stage of development. Fortunately, GlobalData simplifies this process with meticulously crafted, high-value, risk-adjusted NPV models that incorporate extensive drug intelligence.
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – ALG.APV-527 in Malignant Pleural Mesothelioma
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - ALG.APV-527 in Malignant Pleural Mesothelioma report and make more profitable business decisions. This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. ALG.APV-527 in Malignant Pleural Mesothelioma Drug Details: ALG.APV-527 is under...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – Pepinemab in Non-Small Cell Lung Cancer
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - Pepinemab in Non-Small Cell Lung Cancer report and make more profitable business decisions.This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. Pepinemab in Non-Small Cell Lung Cancer Drug Details: Pepinemab (VX-15)...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – Pepinemab in Metastatic Colorectal Cancer
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - Pepinemab in Metastatic Colorectal Cancer report and make more profitable business decisions. This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. Pepinemab in Metastatic Colorectal Cancer Drug Details: Pepinemab (VX-15) is...